Vascepa is a new/first of it's kind/unexpected drug that may well turn the drug business on its head. This alone will cause disruptions and changes in the industry in ways that even now cannot be foreseen. At the very least, Vascepa is going to create change and change is threatening.
The BP s know the generics will not prevail. If the generics prevail over AMRN in spite of AMRN's numerous and comprehensive patents...….then the patent system is meaningless.....this is not going to happen!
It is obvious to the BP s that Vascepa is real and will change things...….they better get busy on coming up with a plan B.
In the meantime they may use anything they can to delay and stand in the way of AMRN. BP can get "branded" Vascepa any time they want. Make a public offer of $100.00 a share and Vascepa belongs to big BP.
Why not do what they can to discourage impatient AMRN shareholders and get Vascepa a little cheaper...….
News 
Market Data 
Discover 
